 | | Vol. 5.37 – 8 October, 2021 |
| |
|
|
| Researchers studied the spatial metabolic profile in the human fibrotic liver. They discovered subpopulations of hepatocytes with special metabolic features associated with their proximity to the fibrotic niche, and validated this finding by spatial transcriptomics with Geo-seq.
[Nature Methods] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Hepatocyte-specific inactivation of ZBTB20 in mice led to a remarkable increase in lipoprotein lipase (LPL) expression at the mRNA and protein levels in adult liver, in which LPL protein was mainly localized onto sinusoidal epithelial cells and Kupffer cells.
[Hepatology] |
|
|
|
| The authors described a previously unrecognized role for pseudogenes as potent epigenetic regulators that could demethylate and activate oncogenes. They focused on SALL4, a known oncogene in hepatocellular carcinoma with eight pseudogenes.
[Science Advances] |
|
|
|
| Scientists found that liver-specific deletion of Ssu72 phosphatase in mice led to a high incidence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, but not hepatocellular carcinoma.
[Cell Death & Differentiation] |
|
|
|
| Investigators reported that metformin treatment increased the sensitivity of hepatocarcinoma cells to methotrexate by suppressing the expression of the one-carbon metabolism enzyme dihydrofolate reductase.
[Cell Death & Disease] |
|
|
|
| Spheroid cultures of primary human hepatocytes are used in studies of hepatic drug metabolism and toxicity. The authors performed an in-depth analysis of the influence of various culture conditions to find the optimal conditions for the maintenance of an in vivo like phenotype.
[iScience] |
|
|
|
| Leveraging The Cancer Genome Atlas to perform a combined analysis of cholangiocarcinoma and hepatocellular carcinoma, investigators integrated multiple genomic platforms to uncover underlying etiology and lineage-specific patterns.
[Communications Biology] |
|
|
|
| Researchers reported a method for seeding and engrafting primary porcine hepatocytes into a bioengineered liver scaffold previously reendothelialized with human umbilical vein endothelial cells.
[Communications Biology] |
|
|
|
| The authors showed that ERRFI1 was upregulated in sensitive hepatocellular carcinoma (HCC) cells, but not in resistant HCC cells, in response to tryptophan deficiency, and ERRFI1 expression level positively correlated with HCC patient overall survival.
[Cell Death Discovery] |
|
|
|
| Curcumin (CCM) was investigated for inhibitory action toward hepatitis B virus attachment and internalization. Immortalized hepatocyte-like cells, HepaRG, and non-hepatic cells served as host cells for binding study with CCM.
[Scientific Reports] |
|
|
|
| Investigators utilized in vitro transcribed mRNA to introduce Na+-taurocholate-cotransporting polypeptide (NTCP) into cells. After transfection of mRNA, surface expression and functionality of NTCP was demonstrated by staining with an N-terminal HBV-preS peptide and bile acid uptake.
[Scientific Reports] |
|
|
|
|
| Cholestatic and non-alcoholic fatty liver disease share several key pathophysiological mechanisms which can be targeted by novel therapeutic concepts that are currently developed for both areas.
[Gut] |
|
|
|
| The authors review recent progress of ferroptosis studies delineating molecular mechanisms underlying the pathophysiology of several common liver diseases including nonalcoholic fatty liver disease, alcoholic liver disease, hemochromatosis, drug-induced liver injury, and hepatocellular carcinoma.
[Cell Death Discovery] |
|
|
|
|
| Merck announced that the Phase III KEYNOTE-394 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in Asian patients with advanced hepatocellular carcinoma previously treated with sorafenib met its primary endpoint of overall survival.
[Merck] |
|
|
|
| Surface Oncology, a company developing immunotherapies that target the tumor microenvironment, announced details about its plan to initiate a randomized Phase II clinical study evaluating SRF388 in patients with treatment-naïve hepatocellular carcinoma.
[Surface Oncology] |
|
|
|
|
| November 1 – 3, 2021
Virtual |
|
|
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| | Novo Nordisk – Indianapolis, Indiana, United States |
|
|
|
| | UConn Health – Farmington, Connecticut, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
